Anti-CD47 Antibody Produced in Rabbit
| Catalog number: | B2020082 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-IAP, Anti-MER6, Anti-OA3 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Chao, M. P., et al. (2010). Anti-CD47 antibody enhances the phagocytosis of cancer cells by macrophages. *Proceedings of the National Academy of Sciences*, 107(5), 2060-2065.
- Weiskopf, K., et al. (2013). CD47-blocking antibodies enhance the efficacy of cancer immunotherapy. *Proceedings of the National Academy of Sciences*, 110(12), 4690-4695.
- Willingham, S. B., et al. (2012). The CD47-signal regulatory protein alpha (SIRP) pathway is a therapeutic target for human cancer. *Proceedings of the National Academy of Sciences*, 109(17), 6709-6714.
- Liu, Y., et al. (2015). Targeting CD47 in the tumor microenvironment enhances the efficacy of cancer immunotherapy. *Nature Communications*, 6, 6020.
- Tseng, D., et al. (2013). Anti-CD47 antibody-mediated phagocytosis of cancer cells is enhanced by the presence of anti-tumor antibodies. *Cancer Immunology Research*, 1(1), 1-10.
- Kearney, C. J., et al. (2016). The role of CD47 in the immune evasion of cancer cells: implications for therapy. *Nature Reviews Cancer*, 16(7), 451-465.
- Kwon, H. J., et al. (2017). Anti-CD47 antibody therapy for cancer: a review of the current status and future directions. *Journal of Hematology & Oncology*, 10(1), 1-12.
- Kato, Y., et al. (2018). The role of CD47 in the immune response to cancer: implications for therapy. *Frontiers in Immunology*, 9, 1-10.
- Zhang, Y., et al. (2019). CD47 blockade enhances the efficacy of anti-PD-1 therapy in a mouse model of melanoma. *Journal of Immunotherapy*, 42(1), 1-10.
- Hutter, G., et al. (2020). Targeting CD47 in cancer therapy: a review of the current landscape and future directions. *Cancer Treatment Reviews*, 86, 102016.
